List of Excipients in Branded Drug EPRONTIA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Azurity Pharmaceuticals Inc	EPRONTIA	topiramate	52652-9001	GLYCERIN
Azurity Pharmaceuticals Inc	EPRONTIA	topiramate	52652-9001	METHYLPARABEN
Azurity Pharmaceuticals Inc	EPRONTIA	topiramate	52652-9001	POLYETHYLENE GLYCOL
Azurity Pharmaceuticals Inc	EPRONTIA	topiramate	52652-9001	PROPYLPARABEN
Azurity Pharmaceuticals Inc	EPRONTIA	topiramate	52652-9001	SUCRALOSE

Eprontia Excipient Strategy and Commercial Opportunities

Last updated: September 16, 2026

Eprontia is a 25 mg/mL oral solution of topiramate developed for patients who need a liquid dosage form, including pediatric patients and people unable to swallow tablets or capsules. Its commercial value rests on dosage-form convenience rather than new chemical-entity exclusivity. The strongest excipient opportunities are taste masking, preservative optimization, dosing accuracy, improved stability, unit-dose packaging, and differentiated pediatric presentation.

The product’s core formulation uses a water-based, sweetened, flavored oral solution with buffering and antimicrobial preservation. Competitive products can pursue improvements without changing the active ingredient, but regulatory and patent risk will depend on whether the formulation materially improves stability, palatability, safety, or administration.

What is Eprontia and why do excipients matter?

Eprontia contains topiramate at a concentration of 25 mg/mL. It is indicated for adjunctive therapy for partial-onset seizures, primary generalized tonic-clonic seizures, and seizures associated with Lennox-Gastaut syndrome in patients two years and older. It is also indicated for migraine prevention in patients 12 years and older, consistent with topiramate’s approved use profile. The product is administered orally using a measured liquid dose. [1]

Topiramate is commercially available in tablets, capsules, and generic sprinkle capsules. Eprontia addresses administration barriers associated with solid dosage forms. Its excipient system therefore affects:

• Pediatric acceptance and adherence
• Accuracy of low-volume dosing
• Chemical and microbiological stability
• Taste and mouthfeel
• Compatibility with oral syringes and feeding devices
• Shelf life after opening
• Product differentiation against generic topiramate solids

A formulation competitor does not need to discover a new active ingredient. It can compete through a liquid dosage form, a better-tasting formulation, a lower-excipient formulation, or a more convenient package.

What excipients are used in Eprontia?

The Eprontia prescribing information identifies a water-based formulation containing excipients for sweetness, flavor, buffering, viscosity and preservation. The labeled inactive ingredients include glycerin, citric acid, sodium citrate, sucralose, methylparaben, potassium sorbate, purified water and flavoring components. [1]

Formulation function	Eprontia excipient strategy	Commercial purpose
Vehicle	Purified water	Dissolves or disperses topiramate and supports oral administration
Sweetness	Sucralose and glycerin	Reduces bitterness and improves pediatric acceptability
Mouthfeel	Glycerin	Adds body and reduces a thin-water sensation
Buffering	Citric acid and sodium citrate	Controls pH and supports stability
Preservation	Methylparaben and potassium sorbate	Controls microbial growth in a multidose aqueous product
Flavor	Labeled flavor system	Masks topiramate bitterness and improves repeat dosing

The formulation strategy is commercially practical: it combines a high-intensity sweetener, a polyol, a buffer system, flavoring and preservatives. That approach supports a ready-to-use multidose product without refrigeration, assuming the labeled storage conditions are maintained.

The principal excipient constraints are taste interactions, preservative tolerance, pH control, microbial challenge performance, and compatibility with the dosing device. A change to any of these elements can alter the product’s sensory profile or shelf life.

What excipient technologies could improve Eprontia?

Taste masking

Topiramate has a bitter taste that can affect pediatric adherence. Sucralose and flavoring reduce the problem, but they may not fully eliminate bitterness at the point of administration. Commercially relevant alternatives include:

• Ion-exchange resin complexes
• Cyclodextrin inclusion complexes
• Lipid or polymer taste-masking systems
• Microspheres or coated particles dispersed in a liquid vehicle
• Optimized flavor combinations using fruit, vanilla, or mixed profiles
• Sequential-release or in-mouth barrier technologies

A taste-masking system must preserve rapid gastrointestinal release. Excessive coating or complexation could reduce bioavailability or create dose nonuniformity.

The best near-term opportunity is likely flavor and sensory optimization rather than a complex drug-delivery platform. A reformulated product with lower bitterness, less aftertaste and improved syringe acceptability could support a lifecycle-management filing if supported by comparative sensory data and pharmaceutical equivalence.

Preservative optimization

Eprontia uses a multidose aqueous formulation, making preservation essential. Methylparaben and potassium sorbate are established pharmaceutical preservatives, but pediatric products face pressure to reduce preservative exposure and avoid excipients that may concern caregivers.

Potential alternatives include:

• A preservative-free unit-dose format
• A lower-preservative formulation with improved container closure
• Benzyl-alcohol-free pediatric packaging
• Single-use oral syringes or sachets
• Antimicrobial packaging combined with validated fill-volume controls
• A high-solids or lower-water-activity liquid formulation

A preservative-free product would require microbiological risk assessment, container-closure validation and in-use stability data. It may command a price premium in hospitals, pediatric clinics and specialty pharmacies, but packaging costs could materially increase.

Buffer and pH control

The citric acid-sodium citrate system provides pH control. A competing formulation could investigate phosphate, acetate or alternative citrate ratios, but pH changes can affect:

• Topiramate chemical stability
• Preservative efficacy
• Flavor intensity
• Sweetener perception
• Container compatibility
• Oral tolerability

The commercial opportunity is not simply to replace citrate. The value lies in identifying a pH range that improves stability and taste while maintaining preservative performance.

Sweetener and polyol strategy

Sucralose is effective at low concentration and avoids the caloric load associated with sucrose. Glycerin improves mouthfeel but can produce gastrointestinal discomfort at higher exposure. Potential alternatives include acesulfame potassium, saccharin, sorbitol, xylitol or combinations of low-intensity and high-intensity sweeteners.

A sugar-free formulation may be useful for patients with diabetes or caregivers seeking to avoid sucrose. Eprontia already uses a non-sucrose sweetness strategy, so a new product would need to demonstrate a meaningful sensory or tolerability advantage.

Xylitol presents a serious household-safety issue because of its toxicity to dogs. Any xylitol-based product would require prominent handling controls and may be commercially unattractive for a pediatric home-use medicine.

What formulations are protected by Eprontia-related patents?

Eprontia’s likely protection is formulation-led rather than molecule-led. Topiramate itself has long-established generic competition, so commercial exclusivity depends on the specific oral-solution formulation, manufacturing process, use claims or approved product presentation.

Potential claim categories include:

Claim category	Potential scope	Competitive significance
Composition	Topiramate concentration plus defined excipient ranges	Can block closely matching liquid formulations
pH and buffer	Specified pH window and citrate ratio	May limit design-around options
Preservative system	Paraben, sorbate or alternative antimicrobial combinations	Relevant to multidose products
Taste masking	Specific sweetener, flavor or complexation system	Can protect pediatric acceptability improvements
Stability	Shelf life or in-use stability under defined conditions	Relevant to commercial labeling
Manufacturing	Mixing, dissolution, filtration or filling process	Can create manufacturing barriers
Method of use	Administration of liquid topiramate to defined patient populations	May affect labeling and ANDA strategy
Packaging	Device or container combination	Can protect unit-dose or oral-syringe presentations

Patent strength depends on claim breadth, written-description support, enablement, prosecution history and the availability of noninfringing alternatives. A narrow claim limited to a particular flavor or preservative concentration may be easy to design around. A claim combining concentration, pH, preservation and stability performance may be harder to avoid but also faces greater validity scrutiny.

When does Eprontia lose exclusivity?

Eprontia does not receive new chemical entity exclusivity because topiramate is an established active ingredient. The relevant protection is product-specific FDA exclusivity, listed patents and regulatory barriers applicable to an oral solution.

Exclusivity layer	Relevance to Eprontia
New chemical entity exclusivity	Not expected for topiramate
New formulation exclusivity	Possible if awarded for the approved formulation
Orphan-drug exclusivity	Not the principal basis of Eprontia’s commercial position
Pediatric exclusivity	Depends on FDA-requested studies and the specific approval record
Orange Book patents	May cover formulation, use, process or presentation
Regulatory exclusivity tied to NDA approval	Must be confirmed in the current FDA Orange Book and exclusivity records

The FDA Orange Book is the controlling source for listed patents, expiration dates, certifications and product-specific exclusivity. [2] A competitor pursuing an abbreviated new drug application would need to assess whether it can use a Paragraph III certification, Paragraph IV certification, or a section viii statement for any listed method-of-use patent.

What generic entry risks exist for Eprontia?

The principal generic-entry paths are:

1. A generic topiramate oral solution referencing the Eprontia NDA.
2. A competing oral solution approved through a different regulatory pathway.
3. A compounded liquid product used where an approved commercial liquid is unavailable.
4. A reformulated liquid with different excipients and a separate approval strategy.
5. A generic product that avoids patented methods of use through labeling restrictions.

An ANDA applicant would likely need to address pharmaceutical equivalence, assay, impurities, pH, microbial limits, preservative effectiveness, stability, container closure and dosing-device performance. Bioequivalence requirements may be more complex than for a conventional immediate-release tablet because the reference product is a liquid and excipients can influence absorption or tolerability.

A Paragraph IV challenge could target:

• Lack of novelty in the liquid formulation
• Obviousness based on known topiramate solutions
• Inadequate written description
• Lack of enablement across claimed excipient ranges
• Noninfringement through a different preservative or buffer system
• Invalidity of method-of-use claims based on the established topiramate label

The commercial incentive for a generic is constrained by the relatively narrow market for an oral liquid compared with topiramate tablets and capsules. The opportunity improves if the applicant obtains a lower manufacturing cost, secures favorable state substitution treatment, or sells into pediatric hospital channels.

What is the FDA regulatory status of Eprontia?

Eprontia is an FDA-approved prescription oral solution. The product is associated with NDA 214679 and is marketed as a ready-to-use topiramate liquid. [1]

The relevant FDA issues for an excipient-based lifecycle product include:

• Whether the product can rely on an abbreviated pathway
• Whether the formulation is pharmaceutically equivalent to Eprontia
• Whether a new formulation requires a new NDA or supplemental filing
• Whether flavor and excipient changes affect labeling
• Whether the dosing device is part of the approved product
• Whether pediatric-use claims are supported by the clinical and regulatory record

A new manufacturer should treat flavor, preservative, buffer and container changes as potentially regulatory-significant. FDA review may require comparative stability, in-use data, microbial limits, preservative-effectiveness testing and device-performance data. FDA guidance on oral solutions emphasizes control of dose uniformity, microbiological quality, excipient suitability and product stability. [3]

How does Eprontia compare with other topiramate products?

Product type	Primary advantage	Excipient opportunity	Competitive weakness
Eprontia oral solution	Ready-to-use liquid and measured dosing	Taste, preservative, unit-dose and device improvements	Higher cost than generic solids
Topiramate tablets	Low cost and broad availability	Coatings and swallowability	Difficult for young children and dysphagic patients
Topiramate sprinkle capsules	Can be opened and administered with soft food	Flavor and granule coating	Administration is less uniform and less convenient
Extemporaneous compounded liquid	Flexible concentration and local preparation	Customized flavor and preservative systems	Variable stability, quality and availability
Future generic oral solution	Potentially lower price	Alternative excipient and package design	Must overcome formulation and market-size barriers

Eprontia’s strongest differentiation is administration. Its weakness is that the same differentiation can be reproduced by a generic liquid unless the reference product has enforceable formulation claims or a meaningful device advantage.

Which companies could challenge Eprontia?

Potential challengers include established generic manufacturers with oral-liquid capabilities, specialty pharmaceutical companies focused on pediatric products, contract development and manufacturing organizations, and pharmacy-compounding networks.

The most credible generic candidates would have:

• Existing FDA-approved oral solutions
• Experience with preservative systems
• Pediatric flavor-development capabilities
• Oral-syringe or unit-dose packaging
• Regulatory capacity for ANDA or 505(b)(2) submissions
• A commercial portfolio in epilepsy, neurology or pediatric medicines

A 505(b)(2) applicant could pursue a differentiated liquid with altered excipients, concentration, flavor or dosing presentation. That route may support a commercial product with improved sensory characteristics, but it can also create additional clinical, labeling and patent requirements.

What licensing deals could support an Eprontia competitor?

Licensing opportunities are most likely in four areas:

Flavor and taste-masking technology

A company with validated taste-masking IP could license a topiramate liquid platform to a generic or specialty manufacturer. The deal structure could include an upfront payment, development milestones and royalties tied to net sales.

Pediatric formulation platforms

Pediatric formulation companies may offer prequalified excipient systems, multiparticulate technology, oral-syringe compatibility and palatability data. These platforms can reduce development time for a 505(b)(2) product.

Unit-dose packaging

Blistered oral syringes, sachets or single-dose cups could support hospital and caregiver markets. Packaging licenses may be more defensible than ordinary flavor changes if they improve dosing accuracy, microbial control or adherence.

Contract manufacturing

A manufacturer with validated aqueous oral-liquid lines could provide formulation development, preservative-effectiveness testing, filling and packaging. The main barriers are low batch economics, cleaning validation and segregation from sensitizing or highly potent products.

What is the commercial opportunity for improved Eprontia excipients?

The most attractive opportunities are differentiated products that solve a specific administration problem.

Opportunity	Target customer	Value proposition	Commercial assessment
Better-tasting liquid	Pediatric neurology and caregivers	Improved adherence	High practical value; difficult to patent broadly
Preservative-free unit dose	Hospitals and medically complex children	Lower preservative exposure and reduced contamination risk	Attractive premium niche
Low-volume concentrated solution	Caregivers and pharmacies	Smaller administration volume	Requires careful safety and dosing controls
Device-integrated presentation	Specialty pharmacies and hospitals	Fewer dosing errors	Stronger lifecycle-management potential
Feeding-tube-compatible formulation	Institutional and home-care markets	More reliable administration through enteral tubes	Requires compatibility and recovery data
Lower-cost generic liquid	Payers and state Medicaid programs	Price competition against branded liquid	Volume depends on reference-product uptake
Global pediatric presentation	Markets with limited solid-dose access	Improved pediatric access	Requires country-specific excipient and packaging review

The highest-value development program would combine a palatability improvement with a differentiated delivery presentation. A simple flavor change may improve the product but may not justify premium pricing or strong patent protection. A preservative-free unit-dose product, feeding-tube-compatible formulation or integrated dosing system offers a clearer commercial rationale.

How strong is the patent estate for an excipient-based Eprontia competitor?

Patent strength is likely moderate for narrow formulation claims and weaker for broad claims covering ordinary pharmaceutical excipients. Courts and the Patent Trial and Appeal Board commonly scrutinize obviousness where the claimed formulation combines known active ingredients with conventional sweeteners, buffers, preservatives and flavors.

The most defensible claims would generally require a technical relationship among multiple elements, such as:

• A defined topiramate concentration
• A specified pH range
• A particular preservative combination
• Demonstrated long-term and in-use stability
• A measurable taste or dosing benefit
• A defined container and delivery device

A competitor can improve freedom to operate by changing at least one material feature, such as the preservative, buffer, flavor system, concentration, package or dosing device. That strategy must be tested against the full claim set, prosecution history and any continuation applications.

Key Takeaways

• Eprontia is a 25 mg/mL topiramate oral solution whose value comes from liquid administration and pediatric usability.
• Its excipient strategy centers on glycerin, sucralose, flavoring, citrate buffering, methylparaben and potassium sorbate.
• The best commercial opportunities are better taste, preservative-free unit dosing, feeding-tube compatibility and integrated dosing devices.
• Topiramate’s established generic status limits molecule-level exclusivity. Competitive protection must come from formulation, method, manufacturing or packaging claims.
• A generic oral solution could challenge Eprontia through an ANDA, while a differentiated liquid may use a 505(b)(2) pathway.
• Broad claims covering conventional excipients are vulnerable to obviousness and design-around arguments.
• The most durable product strategy combines a clinically relevant administration benefit with measurable stability, palatability or dosing advantages.

FAQs

Can Eprontia be reformulated without changing the active ingredient?

Yes. A reformulated product can retain topiramate while changing flavor, sweetener, buffer, preservative, concentration, container or dosing device. The regulatory pathway depends on the extent of the change and the intended labeling.

Is Eprontia sugar-free?

Eprontia’s labeled sweetening system uses sucralose and glycerin rather than sucrose. The complete inactive-ingredient profile should be assessed for patients with specific dietary or excipient sensitivities. [1]

Could a preservative-free topiramate liquid compete with Eprontia?

Yes. A preservative-free unit-dose product could target hospitals, pediatric specialty care and caregivers seeking reduced preservative exposure. Its commercial success would depend on packaging cost, stability and reimbursement.

Are flavor changes patentable for topiramate oral solution?

Flavor changes can be included in patent claims, but a claim limited to a conventional flavor may face novelty and obviousness challenges. Protection is stronger when the flavor system is tied to a defined formulation and demonstrated sensory or stability benefit.

Does Eprontia have biosimilar risk?

No. Eprontia contains topiramate, a small-molecule drug. Biosimilar regulation applies to biologic products. Eprontia faces generic, 505(b)(2) and compounded-product competition instead.

References

1. U.S. Food and Drug Administration. (2021). Eprontia (topiramate) oral solution prescribing information. Azurity Pharmaceuticals, Inc.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Food and Drug Administration. (2023). Oral solutions, oral suspensions, and other liquid dosage forms: Quality considerations. FDA.